

510(k) Summary - Elecsys LH CalSet II

Introduction According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence

Submitter name, address, contact Roche Diagnostics Corporation
9115 Hague Rd
Indianapolis IN 46250
(317) 521-3831

Contact person: Theresa M. Ambrose

Date prepared: April 24, 2003

Device Name Proprietary name: Elecsys LH CalSet II

Common name: Calibrator

Classification name: Calibrator, secondary

Device description Elecsys LH CalSet II consists of a lyophilized human serum matrix with added LH.

Intended use The Elecsys LH CalSet II is used for calibrating the quantitative LH assay on the Elecsys immunoassay systems.

Predicate Device We claim substantial equivalence to the currently marketed Elecsys LH CalSet . (K964694).

510(k) Summary – COBAS Integra Creatinine plus ver.2,
continued

Reagent Summary The following table compares the Elecsys LH CalSet II and the predicate device.

Topic	LH CalSet (K964694)	LHCalSet II (Modified Device)
Intended Use	The Elecsys LH CalSet is used for calibrating the quantitative LH assay on the Elecsys 1010/2010 and MODULAR ANALYTICS E170 immunoassay system.	The Elecsys LH CalSet II is used for calibrating the quantitative LH assay on the Elecsys immunoassay systems.
Matrix	Buffer/ protein matrix	Human serum matrix
Storage form	Liquid	Lyophilized
Levels	Low: approx. 1 mIU/mL High: approx 45 mIU/mL	Same
Standardization	Calibrated against 2 nd International Standard (NIBSC) 80/552	Same
Stability	Unopened at 2-8°C: up to expiration date After opening, in aliquots: 12 weeks at 2-8°C Onboard 2010/1010 (20-25 °C): up to 5 hours total E170: use only once	Store at 2-8°C Lyophilized calibrators : up to expiration date Reconstituted: at -20 °C: 1 month (freeze only once) On board: use only once



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

MAY 12 2003

Theresa M. Ambrose, Ph.D., FACB
Regulatory Principle, Centralized Diagnostics
Roche Diagnostics Corporation
9115 Hague Road
P.O. Box 50457
Indianapolis, IN 46250-0457

Re: k031299
Trade/Device Name: Elecsys LH CalSet II
Regulation Number: 21 CFR 862.1150
Regulation Name: Calibrator
Regulatory Class: Class II
Product Code: JIT
Dated: April 24, 2003
Received: May 1, 2003

Dear Dr. Ambrose:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive style.

Steven I. Gutman, M.D., M.B.A.
Director
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure


Indications for Use Statement

510(k) Number (if known): N/A

Device Name: Elecsys LH CalSet II

Indications For Use:

The Elecsys LH CalSet II is used for calibrating the quantitative LH assay on the Elecsys immunoassay systems.



(Division Sign-Off)
Division of Clinical Laboratory
510(k) Number K031299

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use OR Over-The-Counter Use _____
(Per 21 CFR 801.109)

(Optional Format 1-2-96)